Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 5/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8012052 | 0.84 | BRD4 (0.41) | BRD4CREBBPCSF1RNTRK1NTRK2 | |
| SCHEMBL19538841 | 0.84 | NTRK1 (0.34) | BRD4CREBBPCSF1RNTRK1NTRK2 | |
| SCHEMBL19538828 | 0.83 | BRD4 (0.46) | BRD4CREBBPCSF1RDGAT1 | |
| SCHEMBL189854 | 0.82 | BRD4 (0.46) | BRD4CREBBPCSF1RDGAT1 | |
| SCHEMBL29868688 | 0.82 | BRD4 (0.46) | BRD4CREBBPDGAT1 | |
| SCHEMBL8014137 | 0.80 | BRD4 (0.44) | BRD4CREBBPDGAT1 | |
| SCHEMBL17457845 | 0.79 | BRD4 (0.44) | BRD4CREBBPCSF1RDGAT1 | |
| SCHEMBL8028228 | 0.78 | BRD4 (0.43) | BRD4CREBBPCSF1RNTRK1NTRK2 | |
| SCHEMBL8012757 | 0.77 | BRD4 (0.47) | BRD4CREBBPCSF1R | |
| SCHEMBL25786293 | 0.76 | SRC (0.39) | CSF1RNTRK1NTRK2LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, CREBBP, HDAC1 | BRD4 18/4885CREBBP 2/4885CSF1R 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.